Able Labs (CEO Shin Sang) , a company specializing in bio-experimental automation robots and solutions, has been selected for the Ministry of Trade, Industry and Energy’s Materials and Components Technology Development Project. This project aims to mass-produce high-quality organoid regenerative therapies, and Able Labs will participate as the lead company in the third subproject that leads the development of automated process equipment.
Organoids are attracting attention as innovative tools in the fields of patient-tailored treatment and precision medicine. In particular, in the development of regenerative therapies, organoids offer higher biocompatibility and efficacy than existing cell therapies or drug models, and are positioned as the core of next-generation biotherapeutics. However, the production process of organoid regenerative therapies worldwide is currently mostly dependent on manual labor, resulting in quality deviations and continuous difficulties in mass production.
Through this project, Able Labs plans to build the world’s first mass production automation system that will overcome these limitations. The core goal of this project is to develop a technology that can stably mass-produce organoids of uniform quality without relying on workers by automating and standardizing the organoid production process.
This research and development project consists of three sub-projects. The first sub-project deals with the development of key materials and culture vessels for mass production of high-quality organoids, and the second sub-project deals with the development of key components that can evaluate and monitor quality in real time during the production process. The third sub-project led by Able Labs focuses on the development of automated devices that will implement the mass production process based on these research results. In this process, Able Labs will work with ATI Co., Ltd., Neuromeca Co., Ltd., and the Korea Institute of Machinery and Materials to create the optimal technological solution.
Able Labs plans to actively utilize its previous research experience in carrying out this task. Able Labs already has research results on automating organoid-based drug screening using its automated robot NOTABLE. This research can replace existing manual processes, standardize experiments, and greatly improve precision and reproducibility. This technology will be an important foundation for realizing the challenging goal of mass producing high-quality organoid regenerative therapeutics.
Shin Sang, CEO of Able Labs, said, “Organoid regenerative therapy is a core technology for future medicine, and developing an automated system that can reliably mass-produce it is an unprecedented innovation task worldwide.” He added, “Through this task, we will minimize quality deviations and maximize productivity, thereby setting a new standard in the global bio market.”
Since its establishment in 2021, Able Labs has been standing out in the field of bio research and diagnostic automation based on precision liquid handling technology and modular automation solutions, and has proven its technological prowess through collaborations with global companies such as Samsung BioLogics. At the upcoming SLAS2025, Able Labs plans to strengthen its position in the global market by unveiling NOTABLE, SUITABLE, and the Organoid Culture Workstation.
- See more related articles
You must be logged in to post a comment.